• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

用于电感耦合等离子体质谱(ICP-MS)的1毫升湿消化法:测定经铂(II)配合物处理的细胞中的铂-DNA加合物。

One-milliliter wet-digestion for inductively coupled plasma mass spectrometry (ICP-MS): determination of platinum-DNA adducts in cells treated with platinum(II) complexes.

作者信息

Yamada Kanae, Kato Naoyuki, Takagi Akimitsu, Koi Minoru, Hemmi Hiromichi

机构信息

Department of Molecular Biology, Faculty of Medicine, Toho University, 5-21-16 Ohmori-Nishi, Ohta-ku, Tokyo, 143-8540, Japan.

出版信息

Anal Bioanal Chem. 2005 Aug;382(7):1702-7. doi: 10.1007/s00216-005-3339-5. Epub 2005 Jun 16.

DOI:10.1007/s00216-005-3339-5
PMID:15959768
Abstract

Platinum (Pt)-DNA adducts formed by the anti-tumor agent cisplatin are recognized by the DNA mismatch repair (MMR) system. To investigate the involvement of MMR proteins including hMLH1 in the removal of these adducts, we developed a mL-scale wet-digestion method for inductively coupled plasma mass spectrometry (ICP-MS). The detection limit was 0.01 ng mL(-1) Pt, which corresponded to 2 pg Pt/microg DNA when 10 microg of DNA was used. The mean relative errors were 5.4% or better for a dynamic range of 0.01-10 ng mL(-1) Pt. DNA (approximately 500 microg) had no matrix effect. To improve the accuracy, DNA preparations were treated with ribonuclease and the apparent reduction in the concentration of Pt was corrected using cellular DNA levels, which were determined with Hoechst 33258. No significant differences were observed, in terms of the formation of Pt-DNA adducts or their removal over 6 h, between hMLH1-deficient HCT116 cells, a human colorectal cancer cell line, and hMLH1-complemented HCT116+ch3 cells (n=5; P>0.05), indicating that the hMLH1-dependent DNA repair systems contribute to neither the formation nor the removal of the adducts at detectable levels. In addition, approximately 19% of the adducts were removed within 6 h in both cell lines. A time course analysis (~24 h) suggested that the removal of cisplatin-generated Pt-DNA adducts follows first-order kinetics (t(1/2)=32 h). The amount of Pt-DNA adduct formed by oxaliplatin in 1 h was 56% (ratio of means) of that generated by an equimolar concentration of cisplatin in HCT116. The proposed procedure could be useful for determining Pt-DNA adducts formed by Pt(II) complexes.

摘要

由抗肿瘤药物顺铂形成的铂(Pt)-DNA加合物可被DNA错配修复(MMR)系统识别。为了研究包括hMLH1在内的MMR蛋白在去除这些加合物中的作用,我们开发了一种用于电感耦合等离子体质谱(ICP-MS)的毫升规模湿消化方法。检测限为0.01 ng mL⁻¹ Pt,当使用10 μg DNA时,相当于2 pg Pt/μg DNA。在0.01 - 10 ng mL⁻¹ Pt的动态范围内,平均相对误差为5.4%或更低。DNA(约500 μg)没有基质效应。为提高准确性,DNA制剂用核糖核酸酶处理,并使用通过Hoechst 33258测定的细胞DNA水平校正Pt浓度的明显降低。在人结肠癌细胞系hMLH1缺陷的HCT116细胞和hMLH1互补的HCT116 + ch3细胞之间,就Pt-DNA加合物的形成或其在6小时内的去除而言,未观察到显著差异(n = 5;P>0.05),这表明hMLH1依赖的DNA修复系统在可检测水平上对加合物的形成或去除均无贡献。此外,在两个细胞系中,约19%的加合物在6小时内被去除。时间进程分析(约24小时)表明,顺铂生成的Pt-DNA加合物的去除遵循一级动力学(t₁/₂ = 32小时)。在HCT116中,奥沙利铂在1小时内形成的Pt-DNA加合物量是等摩尔浓度顺铂生成量的56%(均值比)。所提出的方法可用于测定由Pt(II)络合物形成的Pt-DNA加合物。

相似文献

1
One-milliliter wet-digestion for inductively coupled plasma mass spectrometry (ICP-MS): determination of platinum-DNA adducts in cells treated with platinum(II) complexes.用于电感耦合等离子体质谱(ICP-MS)的1毫升湿消化法:测定经铂(II)配合物处理的细胞中的铂-DNA加合物。
Anal Bioanal Chem. 2005 Aug;382(7):1702-7. doi: 10.1007/s00216-005-3339-5. Epub 2005 Jun 16.
2
The role of hMLH1, hMSH3, and hMSH6 defects in cisplatin and oxaliplatin resistance: correlation with replicative bypass of platinum-DNA adducts.hMLH1、hMSH3和hMSH6缺陷在顺铂和奥沙利铂耐药中的作用:与铂-DNA加合物复制绕过的相关性。
Cancer Res. 1998 Aug 15;58(16):3579-85.
3
Human colon cancer cells surviving high doses of cisplatin or oxaliplatin in vitro are not defective in DNA mismatch repair proteins.在体外能在高剂量顺铂或奥沙利铂作用下存活的人结肠癌细胞,其DNA错配修复蛋白并无缺陷。
Cancer Chemother Pharmacol. 2002 Jun;49(6):445-52. doi: 10.1007/s00280-002-0450-6. Epub 2002 Apr 20.
4
Determination of cisplatin 1,2-intrastrand guanine-guanine DNA adducts in human leukocytes by high-performance liquid chromatography coupled to inductively coupled plasma mass spectrometry.采用高效液相色谱-电感耦合等离子体质谱联用技术测定人白细胞中顺铂 1,2-内源性鸟嘌呤-鸟嘌呤 DNA 加合物。
Chem Res Toxicol. 2010 Aug 16;23(8):1313-21. doi: 10.1021/tx100023c.
5
Specificity of platinum-DNA adduct repair.铂-DNA加合物修复的特异性
J Inorg Biochem. 1999 Oct;77(1-2):71-81. doi: 10.1016/s0162-0134(99)00149-x.
6
The role of DNA mismatch repair in platinum drug resistance.DNA错配修复在铂类药物耐药中的作用。
Cancer Res. 1996 Nov 1;56(21):4881-6.
7
Inductively coupled plasma mass spectroscopy quantitation of platinum-DNA adducts in peripheral blood leukocytes of patients receiving cisplatin- or carboplatin-based chemotherapy.电感耦合等离子体质谱法定量分析接受顺铂或卡铂化疗患者外周血白细胞中的铂-DNA加合物。
Clin Cancer Res. 1996 Nov;2(11):1829-35.
8
Determination of platinum in human subcellular microsamples by inductively coupled plasma mass spectrometry.电感耦合等离子体质谱法测定人亚细胞微样本中的铂
Anal Biochem. 2007 Apr 1;363(1):135-42. doi: 10.1016/j.ab.2007.01.006. Epub 2007 Jan 10.
9
In vitro studies on the mechanisms of oxaliplatin resistance.奥沙利铂耐药机制的体外研究
Cancer Chemother Pharmacol. 2001 Nov;48(5):398-406. doi: 10.1007/s002800100363.
10
Induction of JNK and c-Abl signalling by cisplatin and oxaliplatin in mismatch repair-proficient and -deficient cells.顺铂和奥沙利铂在错配修复功能正常和缺陷的细胞中对JNK和c-Abl信号通路的诱导作用。
Br J Cancer. 1999 Mar;79(7-8):1104-10. doi: 10.1038/sj.bjc.6690176.

引用本文的文献

1
A sphingolipid-derived paclitaxel nanovesicle enhances efficacy of combination therapies in triple-negative breast cancer and pancreatic cancer.一种源自鞘脂的紫杉醇纳米囊泡可增强三阴性乳腺癌和胰腺癌联合治疗的疗效。
Nat Cancer. 2025 Aug 21. doi: 10.1038/s43018-025-01029-7.
2
A whole genomic CRISPR-Cas9 screen identifies the amino acid transporter (LAT3) as a major determinant of oxaliplatin sensitivity in colorectal cancer cells.一项全基因组CRISPR-Cas9筛选将氨基酸转运体(LAT3)鉴定为结直肠癌细胞中奥沙利铂敏感性的主要决定因素。
bioRxiv. 2025 Apr 24:2025.04.21.649594. doi: 10.1101/2025.04.21.649594.
3
Rapid spectrophotometric determination and extraction of platinum(IV) from pharmaceuticals assisted by 2-(2-(1-(thiophene-2-yl) ethylidene) hydrazinyl) benzoic acid (TEHBA).
在2-(2-(1-(噻吩-2-基)亚乙基)肼基)苯甲酸(TEHBA)辅助下从药物中快速分光光度法测定和萃取铂(IV)
Anal Sci. 2024 Sep;40(9):1765-1777. doi: 10.1007/s44211-024-00612-9. Epub 2024 Jun 17.
4
Encapsulation, controlled release, and antitumor efficacy of cisplatin delivered in liposomes composed of sterol-modified phospholipids.由甾醇修饰磷脂组成的脂质体递送顺铂的包封、控释及抗肿瘤疗效
Eur J Pharm Sci. 2017 May 30;103:85-93. doi: 10.1016/j.ejps.2017.03.003. Epub 2017 Mar 3.
5
DNA Adducts from Anticancer Drugs as Candidate Predictive Markers for Precision Medicine.来自抗癌药物的DNA加合物作为精准医学的候选预测标志物。
Chem Res Toxicol. 2017 Jan 17;30(1):388-409. doi: 10.1021/acs.chemrestox.6b00380. Epub 2017 Jan 3.
6
Oxaliplatin and its enantiomer induce different condensation dynamics of single DNA molecules.奥沙利铂及其对映体诱导单链 DNA 分子不同的凝聚动力学。
PLoS One. 2013 Aug 12;8(8):e71556. doi: 10.1371/journal.pone.0071556. eCollection 2013.
7
Personalized medicine for targeted and platinum-based chemotherapy of lung and bladder cancer.用于肺癌和膀胱癌靶向及铂类化疗的个性化医疗。
Bioanalysis. 2013 Feb;5(3):369-91. doi: 10.4155/bio.12.325.
8
Analysis of the DNA damage produced by a platinum-acridine antitumor agent and its effects in NCI-H460 lung cancer cells.分析铂吖啶抗肿瘤剂引起的 DNA 损伤及其对 NCI-H460 肺癌细胞的影响。
Metallomics. 2012 Jul;4(7):645-52. doi: 10.1039/c2mt20031g. Epub 2012 Mar 29.